Drug pricing

Patients

The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.

News

The Trump administration's long-promised direct-to-consumer (DTC) sales channel for medicines, TrumpRx, has finally gone live.

News

The UK confirms that the cost of the drug pricing deal with the US, initially around £1bn over three years, will be borne by the health department.

News

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.

Market Access

Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate.